{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:40:04Z","timestamp":1747406404235,"version":"3.40.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s10354-014-0338-1","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T10:30:58Z","timestamp":1420713058000},"page":"10-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-TNFs in axial spondyloarthritis","Anti-TNFs bei axialer Spondyloarthritis"],"prefix":"10.1007","volume":"165","author":[{"given":"Roland","family":"Kocijan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Muschitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Rech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"issue":"2","key":"338_CR1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1\u201344.","journal-title":"Ann Rheum Dis"},{"key":"338_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331.","journal-title":"Ann Rheum Dis"},{"key":"338_CR3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrrheum.2012.39","volume":"8","author":"M Rudwaleit","year":"2012","unstructured":"Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol. 2012;8:262\u20138.","journal-title":"Nat Rev Rheumatol"},{"key":"338_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"J Smolen","year":"2014","unstructured":"Smolen J, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6\u201316.","journal-title":"Ann Rheum Dis"},{"key":"338_CR5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"338_CR6","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"338_CR7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.2007.087270","volume":"68","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922\u20139.","journal-title":"Ann Rheum Dis"},{"key":"338_CR8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","volume":"71","author":"J Sieper","year":"2012","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:700\u20136.","journal-title":"Ann Rheum Dis"},{"key":"338_CR9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"338_CR10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349\u201356.","journal-title":"N Engl J Med"},{"key":"338_CR11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2012-202389","volume":"72","author":"IH Song","year":"2013","unstructured":"Song IH, Wei\u00df A, Hermann KG, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1\u00a0year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72:823\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"338_CR12","doi-asserted-by":"crossref","first-page":"A87","DOI":"10.1136\/annrheumdis-2013-eular.313","volume":"72","author":"M Dougados","year":"2013","unstructured":"Dougados M, van der Heijde D, Sieper J, et al. Clinical and imaging efficacy of etanercept in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl 3):A87\u20138.","journal-title":"Ann Rheum Dis"},{"key":"338_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"338_CR14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/ard.2005.045872","volume":"65","author":"J Askling","year":"2006","unstructured":"Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis. 2006;65:707\u201312.","journal-title":"Ann Rheum Dis"},{"key":"338_CR15","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.38014","volume":"65","author":"H Haibel","year":"2013","unstructured":"Haibel H, Heldmann F, Braun J, et al. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. Arthritis Rheum. 2013;65:2211\u20133.","journal-title":"Arthritis Rheum"},{"key":"338_CR16","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2011-201010","volume":"71","author":"IH Song","year":"2012","unstructured":"Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1\u00a0year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2\u00a0year data of the ESTHER trial. Ann Rheum Dis. 2012;71:1212\u20135.","journal-title":"Ann Rheum Dis"},{"key":"338_CR17","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58:1324\u201331.","journal-title":"Arthritis Rheum"},{"key":"338_CR18","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D Heijde van der","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11:R127.","journal-title":"Arthritis Res Ther"},{"key":"338_CR19","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063\u201370.","journal-title":"Arthritis Rheum"},{"key":"338_CR20","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2004.033472","volume":"64","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005;64:1462\u20136.","journal-title":"Ann Rheum Dis"},{"key":"338_CR21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95\u2013100.","journal-title":"Ann Rheum Dis"},{"key":"338_CR22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17\u00a0A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. The Lancet. 2013;382:1705\u201313.","journal-title":"The Lancet"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-014-0338-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-014-0338-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-014-0338-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:16:47Z","timestamp":1747405007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-014-0338-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1007\/s10354-014-0338-1","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"type":"print","value":"0043-5341"},{"type":"electronic","value":"1563-258X"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}